ALVR Stock Report - Alvarion Ltd

AlloVir Inc. (ALVR) is a clinical-stage cell therapy company that focuses on the development of novel allogeneic T cell therapies to treat viral diseases, including those associated with the respiratory syncytial virus (RSV), the coronavirus, and the herpes simplex virus (HSV). AlloVir's proprietary platform technology allows for the selective expansion of virus-specific T cells from healthy donors, which are then infused into patients to help fight off viral infections.

AlloVir's lead product candidate, Viralym-M (ALVR105), is a multi-virus specific T cell therapy designed to treat life-threatening viral infections in patients with severely weakened immune systems, such as those undergoing stem cell transplants. The company is also developing other product candidates targeting specific viral diseases, including ALVR106 for RSV and ALVR109 for HSV.

AlloVir was founded in 2019 and is headquartered in Cambridge, Massachusetts.

Stock Sector: Telecommunications: Communication Equipment